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Antimalarial evaluationAbstract A series of b-benzoylstyrene derivatives of acridine (4a–r) have been synthesized and
characterized using IR, 1H NMR and Mass Spectroscopy. All the compounds were screened for
intraerythrocytic in vitro antimalarial activity against Chloroquine-sensitive (3D7) & Chloro-
quine-resistant (Dd2) strains of Plasmodium falciparum using the SYBR Green I ﬂuorescence assay.
Cytotoxicity study was performed against the HeLa cell line using the MTT assay. Compounds 4c,
4d, and 4l are most potent with IC50 in the range of 0.30–0.52 lM against the 3D7 strain and 0.15–
0.32 lM against the Dd2 strain. The results revealed that antimalarial potency and good resistance
indices were not at the cost of safety since the most potent compounds have turned out to have
promising therapeutic indices in the range of 80–520.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Malaria is an important cause of death and illness in children
and adults, especially in tropical countries. World Health
Organization estimates that half of the world’s population isat risk of malaria. Globally, 300–500 million episodes of
malarial illnesses occur each year, resulting in over one million
deaths from this devastating disease (Lou, et al., 2001; Hay,
et al., 2004). Chloroquine (CQ) (Fig. 1a) and other quinoline
antimalarials such as Amodiaquine (Fig. 1b) and Meﬂoquine
(Fig. 1c) have been the mainstays of malaria chemotherapy
for the past ﬁve decades because of excellent clinical efﬁcacy,
limited host toxicity, ease of use and simple cost-effective syn-
thesis. Unfortunately the efﬁcacy of quinoline based antima-
larial is eroded by the emergence of resistant parasites (Foley
and Tilley, 1998). The development of drug resistance has be-
come a major health concern and has stimulated the search for
alternative antimalarial agents. In this perspective the acridine
nucleus offers an alternative to quinoline moiety. Indeed Quin-
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Figure 1 The 4-aminoquinolines [Chloroquine (a), Amodiaquine (b) and Meﬂoquine (c)], Quinacrine (d), Pyronaridine (e) and b-
benzoylstyrene derivatives of acridine (4a–r).
Synthesis, characterization and antimalarial evaluation of new b-benzoylstyrene derivatives of acridine S275acrine (Fig. 1d) an acridine, was the ﬁrst synthetic antimalarial
used even before Chloroquine (Bruce-Chwatt, 1964). Pyronari-
dine (Fig. 1e), a new acridine based antimalarial developed in
China is effective against Chloroquine resistant strain of Plas-
modium falciparum (Chang, et al., 1992). Acridine derivatives
containing 9-aminoacridine and 9-anilinoacridine scaffolds
have been reported to exhibit antimalarial activity (Obexer,
et al., 1995; Girault, et al., 2000; Chibale, et al., 2001; Santel-
li-Rouvier, et al., 2004; Guetzoyan, et al., 2009; Kumar, et al.,
2009). In general, the acridine moiety has been found to pos-
sess diverse biological attributes including antitumor, (Bagu-
ley, et al., 1981) antiprion, (May, et al., 2006) anti-alzheimer,
(Fang, et al., 2008) antileishmanial and antitrypanosomal
(Gamage, et al., 1994) activities. Various modes of action of
acridine derivatives for their antimalarial effect have been pro-
posed including DNA intercalation, (Chen, et al., 1978) bind-
ing to heme, (Dorn, et al., 1998) and inhibition of the enzyme
topoisomerase II (Gamage, et al., 1994).
Here we report the synthesis, characterization and antima-
larial activity together with resistance and therapeutic
indices of eighteen (4a–r) new b-benzoylstyrene derivatives of
acridine.
2. Materials and methods
Melting points were determined in a Thomas micro hot stage
apparatus and are uncorrected. The progress of the reactions
was monitored by thin layer chromatography (TLC) with
ethyl acetate: hexane (1:1 v/v) as eluent. All solvents were
dried and TLC was carried out on precoated plates (silica
gel 60, F254) and visualized with UV light. Column chroma-
tography was performed on silica gel (100–200). Infrared
spectra were determined as KBr pellets on a Shimadzu model
470 spectrophotometer and are expressed in cm1. 1H NMR
spectra were recorded on a JEOL GSX (270 MHz) spectrom-eter; chemical shifts are expressed in d (ppm). Mass spectral
data were obtained with a Varian CP3800 model and was
performed by the Indian Institute of Chemical Technology
(IICT), Hyderabad; IR analyses were performed by Chouksy
laboratory Indore.1H NMR analysis was performed by IIT
Delhi.
2.1. Synthesis
2.1.1. Synthesis of 4-Chloro-2-(4-methoxyanilino) benzoic acid
(1)
A mixture of 2,4-dichlorobenzoic acid (7.68 g, 40.2 mmol) and
p-anisidine (9.8 g, 79.6 mmol, potassium carbonate (6.9 g,
50.0 mmol) and Cu-powder (40 mesh, 0.24 g, 3 wt.% with re-
spect to the amount of benzoic acid used) was heated in amyl
alcohol (40 mL) containing pyridine (1.21 g, 15 wt.%) for 5 h
under reﬂux. After cooling to room temperature, the solution
was acidiﬁed with hydrochloric acid and the crude product was
ﬁltered off and recrystallized from ethanol to afford the
product.
Yield 55%; m.p.; 206–208 C; IR (KBr) cm1; 3321 (N–H),
3008 (C–H), 2954 (OH), 2833, 1662 (C‚O), 1596, 1570, 1515,
1460, 1426, 1334, 1250, 1232, 1178,1156, 1102, 1038;1H NMR
(DMSO-d6) d in ppm: 3.76 (s, 3H, OCH3), 6.65 (dd, 1H, Ar-
H), 6.77 (d, 1H, Ar-H), 6.95–7.02 (m, 2H, Ar-H), 7.18–7.24
(m, 2H, Ar-H), 7.88 (d, 1H, Ar-H), 9.47 (s, 1H, NH); m/z;
276.7 (100%, (M-H)).
2.1.2. Synthesis of the substituted 6,9-dichloro-2-methoxy
acridine (2)
4-Chloro-2-(4-methoxyanilino) benzoic acid (6.7 mmol) was
dissolved in POCl3 (15 mL) and heated under reﬂux for 6 h.
After cooling to room temperature the reaction mixture was
poured very carefully under vigorous stirring into a mixture
containing crushed ice (200 g), ammonia (100 mL) and chloro-
S276 S.P. Prajapati et al.form (250 mL) keeping the pH during this operation always
>8. The phases were separated and the aqueous phase was ex-
tracted with chloroform (2 · 100 mL), the organic phases were
combined, dried (CaCl2) and evaporated to yield the crude
product that was pure enough for further transformations.
Pure samples were obtained after column-chromatography
Yield 66%; m.p.; 169–172 C; IR (KBr) cm1; 2925, 1633,
1554 (C‚N), 1517, 1476, 1420, 1262, 1062, 1027 (C–N); 1H
NMR (CDCl3): 4.01 (s, 3H OCH3), 7.44–7.49 (m, 2H, Ar-
H), 7.52 (dd, 1H, Ar-H), 8.05 (d, 1H, Ar-H), 8.16 (d, 1H,
Ar-H), 8.28 (d, 1H, Ar-H); m/z; 277.
2.1.3. Synthesis of 1-(4-(6-chloro-2-methoxyacridin-9-ylamino)
phenyl) ethanone (3)
A mixture of 4-aminoacetophenone (0.4 g, 0.003 mol) and 6,9-
dichloro-2-methoxyacridine (0.83 g, 0.003 mol) was dissolved
in ethanol. Few drops of HCI were added to the reaction mix-
ture to catalyze the reaction. The content was reﬂuxed for 8 h.
The mixture was poured into ice-H2O and neutralized with di-
lute ammonium hydroxide. The solid obtained was ﬁltered,
dried and recrystallized in alcohol.
Yield 75%; m.p.; 210–212 C; IR (KBr) cm1: 3433 (NH),
1680 (C=‚O); 1H NMR (CDCl3): 2.17 (s, 3H, CH3), 3.73
(s, 3H, OCH3), 6.80–7.90 (m, 10H, Ar-H), 9.65 (brs, 1H,
NH, exchangeable); m/z; 377.
2.1.4. General procedure for the synthesis of compounds (4a–r)
1-(4-(6-chloro-2-methoxyacridin-9-ylamino) phenyl) ethanone
(1 mmol), substituted aldehydes (1 mmol) and 2.5 mmol of
pulverized sodium hydroxide were dissolved in dry methanol
(5 mL). The reaction mixture was stirred at room temperature
for 8–12 h, the resulting precipitates were ﬁltered off and
recrystallized in ethanol, yields 25–89%.
2.1.4.1. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-phenylprop-2-en-1-one (4a). Orange crystal;
Yield 339.4 mg (73%); m.p.; 256 C; IR (KBr) cm1 3325.8
(N–H), 3096.8 (C–H), 1715.8 (C‚O), 1683.5 (C‚C), 1505.9
(C‚N), 1314.7, 1264.5, 1304.7 (C–N), 853 (C–H arom bend);
1H NMR (DMSO-d6) (d ppm): 11.56 (1H, br s, exchangeable
NH), 8.06 (1H, s, Acri), 7.92 (1H, d, Acri), 7.91 (1H, d, Hb),
7.62 (1H, d, Acri), 7.59 (1H, d, Ha), 7.56 (2H, d, ArH), 7.44
(1H, d, Acri), 7.31 (1H, d, Acri), 7.30 (2H, d, ArH), 7.21
(2H, q, ArH), 7.14 (1H, q, ArH), 6.97 (1H, s, Acri), 6.65
(2H, d, ArH), 3.74 (3H, s, OCH3); m/z; 465.13 [M+1].
2.1.4.2. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-(2-chlorophenyl) prop-2-en-1-one (4b). Orange
crystal; Yield 259 mg (52%); m.p.; 198 C; IR (KBr) cm1
3335.6 (N–H), 3033.9 (C–H), 1732.2 (C‚O), 1639.0 (C‚C),
1505.1 (C‚N), 1244.6, 1192.5, 1223.3 (C–N) 804 (C–H arom
bend); 1H NMR (DMSO-d6) (d ppm): 11.74 (1H, br s,
exchangeable NH), 8.20 (1H, d, Acri), 8.09 (1H, d, Acri),
7.99 (1H, d, Hb), 7.92 (1H, d, Acri), 7.98 (1H, s, Acri), 7.63
(1H, d,Ha), 7.60 (1H, s, Acri), 7.51 (2H, d, ArH), 7.44 (2H,
d, ArH), 7.31 (1H, d, Acri), 7.22 (2H, d, ArH), 6.83 (2H, d,
ArH), 3.64 (3H, s, OCH3); m/z; 499.09 [M+1].
2.1.4.3. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-(2-nitrophenyl) prop-2-en-1-one (4c). Orange
crystal; Yield 316.2 mg (62%); m.p.; 246 C; IR (KBr) cm13355.2 (N–H), 3107.3 (C–H), 1683.0 (C‚O), 1618.8 (C‚C),
1539.9 (C‚N), 1300.7, 1285.1, 1338.6 (C–N) 752 (C–H arom
bend); 1H NMR (DMSO-d6) (d ppm): 11.76 (1H, br s,
exchangeable NH), 8.46 (1H, d, Hb), 8.14 (1H, d, ArH), 8.06
(1H, s, Acri), 7.92 (1H, d, Acri), 7.63 (1H, d,Ha), 7.62 (1H,
d, Acri), 7.60 (1H, q, ArH), 7.56 (1H, d, ArH), 7.56 (2H, d,
ArH), 7.44 (1H, d, Acri), 7.40 (1H, q, ArH), 7.31 (1H, d, Acri),
6.97 (1H, s, Acri), 6.65 (2H, d, ArH), 3.74 (3H, s, OCH3); m/z;
510.11 [M+1].
2.1.4.4. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-(2-methoxyphenyl) prop-2-en-1-one (4d). Or-
ange crystal; Yield 356.3 mg (72%); m.p.; 215 C; IR(KBr)
cm1 3353.7 (N–H), 3097.4 (C–H), 1732.4 (C‚O), 1652.2
(C‚C), 1506.1 (C‚N), 1348.8, 1294.8, 1250.8 (C–N) 798
(C–H arom bend); 1H NMR (DMSO-d6) (d ppm): 11.55
(1H, br s, exchangeable NH), 8.17 (1H, d, Hb), 8.06 (1H, s,
Acri), 7.92 (1H, d, Acri), 7.62 (1H, d, Acri), 7.56 (2H, d,
ArH), 7.44 (1H, d, Acri), 7.39 (1H, d,Ha), 7.31 (1H, d, Acri),
7.19 (1H, d, ArH), 7.03 (1H, q, ArH), 6.97 (1H, s, Acri), 6.77
(1H, d, ArH), 6.72 (1H, d, ArH), 6.65 (2H, d, ArH), 3.74 (3H,
s, OCH3); m/z; 495.14 [M+1].
2.1.4.5. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-(2-hydroxyphenyl) prop-2-en-1-one (4e). Orange
crystal; Yield 264.51 mg (55%); m.p.; 267 C; IR (KBr) cm1
3380.1 (N–H), 3193.5 (OH), 3020.0 (C–H), 1694.0 (C‚O),
1620.9 (C‚C), 1537.9 (C‚N), 1299.2, 1195.4, 1274.3 (C–N)
843 (C–H arom bend); 1H NMR (DMSO-d6) (d ppm): 11.65
(1H, br s, exchangeable NH), 8.16 (1H, s, Acri), 7.95 (1H, d,
Acri), 7.88 (1H, d, Hb), 7.62 (1H, d, Acri), 7.60 (1H, d, Ha),
7.56 (2H, d, ArH), 7.42 (1H, d, Acri), 7.30 (1H, d, Acri),
7.13 (1H, d, ArH), 6.99 (1H, d, ArH), 6.97 (1H, s, Acri),
6.77 (1H, d, ArH), 6.68 (1H, d, ArH), 6.65 (2H, d, ArH),
3.70 (3H, s, OCH3) 5.10 (1H, s,OH); m/z; 481.12 [M+1].
2.1.4.6. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-(3-nitrophenyl) prop-2-en-1-one (4f). Orange
crystal; Yield 351.8 mg (69%); m.p.; 203 C; IR (KBr) cm1
3351.8 (N–H), 3067.1 (C–H), 1682.5 (C‚O), 1621.1 (C‚C),
1540.1 (C‚N), 1300.3 (-NO2), 1245.2, 1293.8 (C–N) 812 (C–
H arom bend); 1H NMR (DMSO-d6) (d ppm): 11.10 (1H, br
s, exchangeable NH), 8.23 (1H, s, ArH), 8.14 (1H, s, Acri),
8.07 (1H, d, ArH), 8.01 (1H, d, Hb), 7.92 (1H, d, Acri), 7.81
(1H, d,Ha), 7.69 (1H, d, ArH), 7.62 (1H, d, Acri), 7.56 (2H,
d, ArH), 7.47 (1H, t, ArH), 7.44 (1H, d, Acri), 7.31 (1H, d,
Acri), 6.97 (1H, s, Acri), 6.65 (2H, d, ArH), 3.76 (3H, s,
OCH3); m/z; 510.11 [M+1].
2.1.4.7. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-(3-methoxyphenyl) prop-2-en-1-one (4g). Or-
ange crystal; Yield 197.98 mg (40%); m.p.; 242 C; IR (KBr)
cm1 3360.8 (N–H), 3066.4 (C–H), 1731.7 (C‚O), 1521.6
(C‚C), 1537.9 (C‚N), 1294.1, 1197.0, 1262.9 (C–N) 752
(C–H arom bend); 1H NMR (DMSO-d6) (d ppm): 11.98
(1H, br s, exchangeable NH), 8.19 (1H, d, Acri), 8.08 (1H, s,
Acri), 7.92 (1H, d, Acri), 7.89 (1H, d, Hb), 7.61 (2H, d,
ArH), 7.56 (1H, d,Ha), 7.41(1H, d, Acri), 7.36 (1H, d,
Acri),7.04 (1H, q, ArH), 6.91 (1H, s, Acri), 6.84 (1H, d,
ArH), 6.81 (1H, s, ArH), 6.65 (2H, d, ArH), 3.71 (6H, s,
OCH3); m/z; 495.14 [M+1].
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no)phenyl)-3-(3, 4 dihydroxyphenyl) prop-2-en-1-one (4h). Or-
ange crystal; Yield 297.7 mg (60%); m.p.; 214 C; IR (KBr) cm
1 3330.7 (N–H), 2993.4 (C–H), 1714.3 (C‚O), 1615.9
(C‚C), 1537.9 (C‚N), 1264.4, 1298.4, 1243.1 (C–N) 815
(C–H arom bend); 1H NMR (DMSO-d6) (d ppm): 11.54
(1H, br s, exchangeable NH), 8.02 (1H, d, Acri), 7.90 (1H, d,
Hb), 7.82(1H, s, Acri), 7.60 (1H, d, Acri), 7.56 (1H, d,Ha),
7.56 (2H, d, ArH), 7.44 (1H, d,Acri), 7.41 (1H, d, ArH), 7.35
(1H, d, Acri), 6.97(1H, s, Acri), 6.80 (2H, d, ArH), 6.69 (1H,
d, ArH), 6.60 (1H, s, ArH), 5.12 (2H, s, OH), 3.74(3H, s,
OCH3); m/z; 497.12 [M+1].2.1.4.9. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-(3, 4-dimethoxyphenyl) prop-2-en-1-one (4i). Or-
ange crystal; Yield 383.2 mg (73%); m.p.; 198 C; IR (KBr) cm
1 3357.0 (N–H), 3059.5 (C–H), 1715.5 (C‚O), 1616.0
(C‚C), 1538.1 (C‚N), 1310.6, 1244.2, 1232.3 (C–N) 748
(C–H arom bend); 1H NMR (DMSO-d6) (d ppm): 11.73
(1H, br s, exchangeable NH), 8.00 (1H, s, Acri), 7.92 (1H, d,
Acri), 7.92 (1H, d, Hb), 7.66 (1H, d, Ha), 7.62 (1H, d, Acri),
7.56 (2H, d, ArH), 7.45 (1H, d, Acri), 7.36 (1H, d, Acri),
6.89 (1H, s, Acri), 6.77 (1H, d, ArH), 6.71 (1H, s, ArH), 6.62
(1H, d, ArH), 6.65 (2H, d, ArH), 3.70 (9H, s, OCH3); m/z;
525.15 [M+1].
2.1.4.10. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-(4-chlorophenyl) prop-2-en-1-one (4j). Orange
crystal; Yield 329.6 mg (66%); m.p.; 248 C; IR (KBr) cm1
3455.3 (N–H), 3090.0 (C–H), 1693.8 (C‚O), 1642.9
(C‚C),1573.5 (C‚N),1249.1, 1323.5, 1249.9 (C–N) 833 (C–
H arom bend); 1H NMR (DMSO-d6) (d ppm): 11.65
(1H,brs,exchangeable NH), 8.07 (1H, d, Acri), 7.92 (1H, s,
Acri), 7.88 (1H, d, Hb), 7.64 (1H, d, Acri), 7.60 (1H, d,Ha),
7.56 (2H, d, ArH), 7.44 (1H, d, Acri),7.38 (2H, d, ArH), 7.38
(1H, d, Acri), 7.22 (2H, d, ArH), 6.97 (1H, s, Acri), 6.82
(2H, d, ArH), 3.70 (3H, s, OCH3); m/z; 499.09 [M+1].
2.1.4.11. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-(4-nitrophenyl) prop-2-en-1-one (4k). Orange
crystal; Yield 306 mg (60%); m.p.; 245 C; IR (KBr) cm1
3333.2 (N–H), 3107.9 (C–H), 1715.8 (C‚O), 1621.7 (C‚C),
1539.1 (C‚N), 1324.9 (-NO2), 1283.4, 1276.2 (C–N) 842 (C–
H arom bend); 1H NMR (DMSO-d6) (d ppm): 11.65 (1H, br
s, exchangeable NH), 8.13 (2H, d, ArH), 8.12 (1H, s, Acri),
8.05 (1H, d, Hb), 7.91(1H, d, Acri),7.80 (1H, d,Ha), 7.67
(1H, d, Acri), 7.52 (2H, d, ArH), 7.50 (2H, d, ArH), 7.38
(1H, d, Acri), 7.33 (1H, d, Acri), 6.95 (1H, s, Acri), 6.63
(2H, d, ArH), 3.70 (3H, s, OCH3); m/z; 510.11 [M+1].
2.1.4.12. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-(4-methoxyphenyl) prop-2-en-1-one (4l). Orange
crystal; Yield 346.5 mg (70%); m.p.; 215 C; IR (KBr) cm1
3452.6 (N–H), 3007.1 (C–H), 1693.9 (C‚O), 1615.1 (C‚C),
1537.9 (C‚N), 1295.4, 1271.6, 1330.2 (C–N) 824 (C–H arom
bend); 1H NMR (DMSO-d6) (d ppm): 11.96 (1H, br s,
exchangeable NH), 8.06 (1H, s, Acri), 7.92 (1H, d, Acri),
7.88 (1H, d, Hb), 7.74 (1H, d,Ha), 7.62 (1H, d, Acri), 7.56
(2H, d, ArH), 7.45 (1H, d, Acri), 7.31 (1H, d, Acri), 7.19
(2H, d, ArH), 6.97 (1H, s, Acri), 6.72 (2H, d, ArH), 6.65
(2H, d, ArH), 3.77 (6H, s, OCH3); m/z; 525.15 [M+1].2.1.4.13. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-(4-hydroxyphenyl) prop-2-en-1-one (4m). Or-
ange crystal; Yield 303 mg (63%); m.p.; 215 C; IR (KBr) cm
1 3300.5 (N–H), 3260.0 (OH), 3103.2 (C–H), 1713.9
(C‚O), 1642.6 (C‚C), 1505.0 (C‚N), 1298.6, 1242.1,
1274.2 (C–N) 736 (C–H arom bend); 1H NMR (DMSO-d6)
(d ppm): 11.86 (1H, br s, exchangeable NH), 8.06 (1H, s, Acri),
7.98 (1H, d, Hb), 7.92 (1H, d, Acri), 7.62 (1H, d, Acri), 7.60
(1H, d,Ha), 7.56 (2H, d, ArH), 7.44 (1H, d, Acri), 7.31 (1H,
d, Acri), 7.13 (2H, d, ArH), 6.97 (1H, s, Acri),6.68 (2H, d,
ArH), 6.65 (2H, d, ArH), 3.74 (3H, s, OCH3) 5.0 (1H, s,
OH); m/z; 481.12 [M+1].
2.1.4.14. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-p-tolyprop-2-en-1-one (4n). Orange crystal; Yield
268.2 mg (56%); m.p.; 210 C; IR (KBr) cm1 3380.9 (N–H),
3005.5 (C–H), 1699.0 (C‚O), 1644.9 (C‚C), 1503.7 (C‚N)
784 (C–H arom bend), 1294.2, 1201.3, 1276.9 (C–N); 1H
NMR (DMSO-d6) (d ppm): 11.86 (1H, br s, exchangeable
NH), 8.06 (1H, s, Acri), 7.92 (1H, d, Acri), 7.90 (1H, d, Hb),
7.73 (1H, d,Ha), 7.62 (1H, d, Acri), 7.52 (2H, d, ArH), 7.44
(1H, d, Acri), 7.33 (1H, d, Acri), 7.18 (2H, d, ArH), 7.01
(2H, d, ArH), 6.97 (1H, s, Acri), 6.65 (2H, d, ArH), 3.71
(3H, s, OCH3), 2.35 (1H, s, CH3); m/z; 479.14 [M+1].
2.1.4.15. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-(4-ethylphenyl) prop-2-en-1-one (4o). Orange
crystal; Yield 315.5 mg (64%); m.p.; 232 C; IR (KBr) cm1
3324.4 (N–H), 3053.2 (C–H), 1694.0 (C‚O), 1621.3 (C‚C),
1537.8 (C‚N), 1203.4, 1298.3, 1276.2 (C–N) 842 (C–H arom
bend); 1H NMR (DMSO-d6) (d ppm): 11.66 (1H, br s,
exchangeable NH), 7.25 (2H, d, ArH), 7.01 (2H, d, ArH),
7.58 (2H, d, ArH), 6.75 (2H, d, ArH), 7.80 (1H, d, Hb), 7.58
(1H, d,Ha), 7.35 (1H, d, Acri), 7.90(1H, d, Acri), 6.97(1H, s,
Acri),7.99 (1H, s, Acri), 7.62(1H, d, Acri), 7.42 (1H, d, Acri),
2.59 (2H, q, CH2), 1.24 (3H, t, CH3),3.71 (3H, s, OCH3); m/
z; 493.16 [M+1].
2.1.4.16. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-(4-(dimethylamino)phenyl) prop-2-en-1-one
(4p). Orange crystal; Yield 376 mg(74%); m.p.; 187 C; IR
(KBr) cm1 3322.7 (N–H), 3122.7 (C–H), 1703.2 (C‚O),
1643.9 (C‚C), 1537.8 (C‚N), 1314.0, 1246.5, 1226.7 (C–N)
762 (C–H arom bend); 1H NMR (DMSO-d6) (d ppm): 11.64
(1H, br s, exchangeable NH), 7.12 (2H, d, ArH), 6.44 (2H,
d, ArH), 7.58 (2H, d, ArH), 6.65 (2H, d, ArH), 7.89 (1H, d,
Hb), 7.43 (1H, d,Ha), 7.30 (1H, d, Acri), 7.92 (1H, d, Acri),
6.97 (1H, s, Acri),8.16 (1H, s, Acri), 7.62 (1H, d, Acri), 7.44
(1H, d, Acri), 3.70 (3H, s, OCH3), 2.59 (6H, s, 2 CH3); m/z;
508.17 [M+1].
2.1.4.17. (E)-4-(3-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-oxoprop-1enyl) benzonitrile (4q). Orange crystal;
Yield 367.5 mg (75%); m.p.; 233 C; IR (KBr) cm1 3376.2
(N–H), 3060.8 (C–H), 1713.5 (C‚O), 1640.7 (C‚C), 1504.7
(C‚N), 1298.2, 1274.1, 1334.1 (C–N) 823 (C–H arom bend);
1H NMR (DMSO-d6) (d ppm): 11.50 (1H, br s, exchangeable
NH), 7.48 (2H, d, ArH), 7.40 (2H, d, ArH),7.56 (2H, d, ArH),
6.65 (2H, d, ArH), 7.85 (1H, d, Hb), 7.54 (1H, d,Ha), 7.30 (1H,
d, Acri), 7.92 (1H, d, Acri), 6.97 (1H, s, Acri), 8.06 (1H, s,
Acri), 7.62 (1H, d, Acri), 7.39 (1H, d, Acri), 3.73 (3H, s,
OCH3); m/z; 490.12 [M+1].
S278 S.P. Prajapati et al.2.1.4.18. (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylami-
no)phenyl)-3-(4-ﬂuorophenyl) prop-2-en-1-one (4r). Orange
crystal; Yield 241.5 mg (50%); m.p.; 195 C; IR (KBr) cm1
3340.1 (N–H), 3050.6 (C–H), 1713.3 (C‚O), 1621.6 (C‚C),
1531.6 (C‚N), 1294.8, 1203.4, 1281.4 (C–N) 807 (C–H arom
bend); 1H NMR (DMSO-d6) (d ppm): 11.61 (1H, br s,
exchangeable NH), 7.28 (2H, d, ArH), 6.92 (2H, d, ArH),
7.56 (2H, d, ArH), 6.65 (2H, d, ArH), 7.83 (1H, d, Hb), 7.68
(1H, d,Ha), 7.33 (1H, d, Acri), 7.92 (1H, d, Acri), 6.97 (1H,
s, Acri), 8.06 (1H, s, Acri), 7.62 (1H, d, Acri), 7.40 (1H, d,
Acri), 3.72 (3H, s, OCH3); m/z; 483.12 [M+1].
3. Antimalarial evaluation
3.1. Measurement of inhibition of P. falciparum growth in
culture
In this study chloroquine sensitive 3D7 and Chloroquine resis-
tant Dd2 strains provided by MR4/ATCC (Manassas, USA)
were used in in vitro culture. Parasite strains were cultivated
by the method of Trager and Jensen (1976) with minor modi-
ﬁcations (Trager and Jensen, 1976). Cultures were maintained
in fresh O+ human erythrocytes at 4% hematocrit in complete
medium [RPMI 1640 (supplemented with 25 mM HEPES and
L-Glutamine) with 0.2% sodium bicarbonate 0.5% Albumax,
45 mg/L hypoxanthine and 50 mg/L gentamicin] at 37 C un-
der reduced O2 (gas mixture 5% O2, 5% CO2, and 90% N2).
Stock solutions of Chloroquine (CQ) were prepared in water
(miliQ grade) and test compounds were dissolved in DMSO.
All stocks were then diluted with Complete culture medium
to achieve the required concentrations (In all cases the ﬁnal
concentration contained 0.4% DMSO, which was found to
be non-toxic to the parasite). CQ and test compounds were
then placed in 96-well ﬂat-bottomed tissue culture grade plates
to yield triplicate wells with drug concentrations ranging from
0 to 104 M in a ﬁnal well volume of 100 ll for primary screen-
ing. Chloroquine was used as a positive control in all experi-
ments. Parasite culture was synchronized at the ring stage
with 5% sorbitol. Synchronized culture was aliquoted to drug
containing a 96-well plate at 2% hematocrit and 1% parasite-
mia. After 48 h of incubation under standard culture condi-
tions, plates were harvested by the addition of SYBR Green
I containing lysis buffer (100 ll) and read by the SYBR Green
I ﬂuorescence-based method (Smilkstein et al. 2004) using a
96-well ﬂuorescence plate reader (Victor, Perkin Elmer), with
excitation and emission wavelengths at 497 and 520 nm,
respectively. The ﬂuorescence readings were plotted against
drug concentration, and IC50 values obtained by visual match-
ing of the drug concentration giving 50% inhibition of growth.
3.2. Measurement of cytotoxic activity against mammalian cell
lines in culture
Animal cell line (Hela) was used to determine drug toxicity by
using MTT assay for mammalian cell viability assay as de-
scribed by Mosmann 1983. Hela cells cultured in complete
RPMI (cRPMI) containing 10% fetal bovine serum, 0.2% so-
dium bicarbonate, 50 mg/L gentamycin. Brieﬂy, Cells
(104 cells/200 ll/well) were seeded into 96-well ﬂat-bottomed
tissue-culture plates in a complete culture medium. Drug solu-
tions were added after overnight seeding and incubated for24 h in a humidiﬁed atmosphere at 37 C and 5% CO2. DMSO
(ﬁnal concentration 10%) was added as +ve control. An ali-
quot of a stock solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (5 mg/mL in 1X phos-
phate-buffered saline) was added at 20 ll per well, and incu-
bated for another 3 h. After spinning the plate at 1500 RPM
for 5 min, supernatant was removed and 100 ll of the stop
agent DMSO was added to the well to dissolve the formazan
crystals. Formation of formazon, an index of growth was read
at 570 nm by a 96-well plate reader (Versa Max) and IC50 val-
ues were determined by analysis of dose–response curves.
Therapeutic index was calculated as IC50 Mammalian cell/
IC50 Pf3D7.
4. Results and discussion
4.1. Chemistry
The synthetic pathway for b-benzoylstyrene derivatives of
acridine (4a–r) is illustrated in Scheme 1. Compound 4-chloro-
2-(4-methoxyanilino) benzoic acid (1) was prepared by per-
forming Ullmann condensation between 2,4-dichlorobenzoic
acid and p-anisidine. Subsequently the reﬂuxing of 4-Chloro-
2-(4-methoxyanilino) benzoic acid in phosphorus oxychloride
resulted in the formation of 6,9-dichloro-2-methoxyacridine
(2) (Csuk, et al., 2004). Condensation of 6,9-dichloro-2-
methoxyacridine and 4-aminoacetophenone afforded 1-(4-(6-
chloro-2-methoxyacridin-9-ylamino) phenyl) ethanone (3)
(Aly and Abadi, 2004). Compound 1-(4-(6-chloro-2-methoxy
acridin-9-ylamino)phenyl) ethanone was reacted with a series
of substituted aromatic aldehydes to obtain b-benzoylstyrene
derivatives of acridine (4a–r) (Table 1). All compounds synthe-
sized as above have been characterized by spectral data (IR,
1H NMR, Mass).
4.2. Antimalarial activity
All the synthesized compounds were evaluated for their anti-
malarial activity against CQ-sensitive (3D7) as well as CQ-
resistant (Dd2) strains of P. falciparum through in vitro red
blood cell based culture using SYBR-Green-I assay (Smilk-
stein et al., 2004). The results of antimalarial potencies are
summarized in Table 1. Variations of different substituents
on the aromatic ring of b-benzoylstyrene derivatives of acri-
dine have been explored to ascertain the structure–activity
relationship among the synthesized compounds of the series.
Among the eighteen evaluated compounds of the series against
CQ-sensitive (3D7), three compounds (4c, 4d, 4l) were most
potent and showed antimalarial IC50 values in the range of
0.30–0.52 lM. Six compounds (4a, 4b, 4f, 4j, 4k, and 4m) dis-
played antimalarial activity in the range 0.7–1.5 lM. Nine
compounds (4e, 4g, 4h, 4i, 4n, 4o, 4p, 4q and 4r) exhibited
the IC50 values ranging from 1.6–4.8 lM. However, activity re-
sults clearly suggest that among the monomethoxy substituted
compounds (4d, 4g, 4l), the 4-substituted methoxy compound
4l is the most potent (IC50 = 0.3 lM). Indeed compound 4l
is six times more active than its 3-methoxy counterpart (com-
pound 4g, IC50 = 1.8 lM) whereas the 2-methoxy substitution
(4d, IC50: 0.52 lM) results in a slight decrease in activity. Addi-
tional methoxy group at position-3 (4i, 3,4-dimethoxy) leads to
a signiﬁcant fall in activity (IC50 = 4.0 lM).
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Scheme 1 Reagents and conditions: (i) K2CO3/Cu/Amyl alcohol, p-anisidine 5 h under reﬂux (ii) POCl3 reﬂux for 6 h (iii) HCl,
Ethanol,110 C for 8 h, (iv) Sodium hydroxide, Methanol, rt, 8–12.
Table 1 In vitro antimalarial activity of title compounds against CQ-sensitive strain (3D7) & CQ resistant strain (Dd2) of P.
falciparum with their resistance & selectivity index on HeLa cell lines.
S. No R IC50 (lM) (3D7) IC50 (lM) Dd2 Resistance index
IC50 Dd2/IC50 3D7
Selectivity index
IC50HeLa/IC50 3D7 IC50HeLa/IC50Dd2
4a H 0.75 0.51 0.68 146.66 215.68
4b 2-Cl 1.5 0.8 0.53 >142 >125
4c 2-NO2 0.35 0.31 0.88 80 90.32
4d 2-OCH3 0.52 0.15 0.28 150 520
4e 2-OH 4.5 5 0.9 22 20
4f 3-NO2 1.3 0.63 0.48 >76 >158
4g 3-OCH3 1.8 0.9 0.5 >66 >111
4h 3,4–OH 2 0.91 0.45 13.5 29.7
4i 3,4-OCH3 4 4.5 1.125 25 22
4j 4-Cl 1.3 0.9 0.69 >76 >111
4k 4-NO2 0.7 0.6 0.85 >166 >117
4l 4-OCH3 0.3 0.3 1 333 333
4m 4-OH 0.8 0.62 0.77 50 64.51
4n 4-CH3 4.8 0.9 0.18 >55 >111
4o 4-C2H5 2.4 1.7 0.70 >41 >58
4p 4-(CH3)2N- 2.5 2.9 1.16 37.6 32.41
4q 4-CN 1.7 1.25 0.73 >58 >80
4r 4-F 2.7 1.7 0.62 >37 >58
CQ 0.04 0.17 4.25 >1000 >1000
Synthesis, characterization and antimalarial evaluation of new b-benzoylstyrene derivatives of acridine S279Isomeric compounds 4c (2-nitro, IC50: 0.35 lM), 4f (3-ni-
tro, IC50: 1.3 lM) and 4k (4-nitro, IC50: 0.7 lM) suggest that
positional isomerism of the Nitro group on the aromatic ring
of b-benzoylstyrene can cause subtle changes in potency. It
was interesting to see over ﬁvefold increase in activity ongoing
from compound 4e (2-hydroxy, IC50: 4.5 lM) to compound
4m (4-hydroxy, IC50: 0.8 lM). The 3, 4-dihyroxy compound
5 (IC50: 2 lM) although less active than compound 4m (4-hy-
droxy, IC50: 0.8 lM) is nevertheless more active than com-
pound 4e (2-hydroxy, IC50: 4.5 lM). With reference to theunsubstituted compound 4a (IC50: 0.75 lM) substitution with
methoxy (compound 4d, IC50: 0.52 lM) or nitro (compound
4c, IC50: 0.35 lM) appeared to potentiate antimalarial activity
while substitutions by hydroxyl (compound 4e, IC50: 4.5 lM)
or chlorine (compound 4b, IC50: 1.5 lM) brought about a
reduction in potency.
The two substitutions at position-3 (methoxy compound 4g,
Nitro compound 4f) indicate that these substitutions lead to
marginal decrease in potency in comparison with the unsubsti-
tuted compound 4a. The compounds 4c and 4l were found to
S280 S.P. Prajapati et al.be nearly equipotent against both Chloroquine sensitive 3D7
and Chloroquine resistant Dd2 strains, giving resistance indices
in the range of 0.88–1. Interestingly compounds 4b, 4d, 4f, 4g,
4h, 4j, 4n, 4o and 4r were found to be more potent against the
Chloroquine resistantDd2 strain than theChloroquine sensitive
3D7 strain resulting in resistance indices in the range of 0.15–0.7.
All the synthesized compounds were further evaluated for
Cytotoxicity by MTT assay (Mosmann, 1983) against HeLa
cell line. Interestingly, as shown in Table 1, all the compounds
evaluated showed good selectivity indices in the range of 20–
520. The compounds 4c, 4d, 4l were the most potent against
malarial parasites also exhibited high selectivity indices in the
range of 80–520.5. Conclusion
In conclusion, there is challenge and urgency to synthesize cost
effective highly potent and less toxic chemotherapeutic agents
for the treatment of malaria after the widespread development
of resistance to chloroquine. As part of our research a series of
eighteen b-benzoylstyrene derivatives of acridine, were synthe-
sized and examined for in vitro antimalarial activity. Com-
pounds 4c, 4d and 4l exhibited very good antimalarial
activity with high selectivity and promising resistance indices.
Further exploration and optimization of b-benzoylstyrene
derivatives of acridine could provide novel antimalarial mole-
cules which can eradicate issues of cross resistance to drugs like
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